Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Myeloid Leukemia, Philadelphia Positive
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 46 (final count)
- Started
- Dec 27, 2021
- Main results expected
- Sep 3, 2027
- Fully finished
- Oct 2, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Primary Pharmacokinetic (PK) parameter: AUClast
Measured over: 52 weeks
Primary PK parameter: AUCtau
Measured over: 52 weeks
Secondary PK parameter: Cmax
Measured over: 52 weeks
Secondary PK parameter: Tmax
Measured over: 52 weeks
Secondary PK parameter: Ctrough
Measured over: 52 weeks
Changes Tremor has spotted
Status changed: Signing up patients → Running, no new patients. Usually normal progress.
Spotted
Moved the final finish date slightly later: Oct 1, 2031 → Oct 2, 2031.
Spotted
Moved the main results date slightly later: Sep 2, 2027 → Sep 3, 2027.
Spotted
Raised the number of patients from 34 to 46.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · status_changed · overall_status
old: "RECRUITING"
new: "ACTIVE_NOT_RECRUITING" - 2026-11-09 15:36 UTC · date_small_change · completion_date
old: "2031-10-01"
new: "2031-10-02"
details: {"months":0} - 2026-11-09 15:36 UTC · date_small_change · primary_completion_date
old: "2027-09-02"
new: "2027-09-03"
details: {"months":0} - 2026-11-09 15:36 UTC · enrollment_increased · enrollment
old: 34
new: 46
details: {"new_type":"ACTUAL","old_type":"ESTIMATED"}
Trial ID NCT04925479 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC